178 related articles for article (PubMed ID: 33423932)
21. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
[TBL] [Abstract][Full Text] [Related]
22. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
23. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
25. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P; Fronkova E; Belada D; Forsterova K; Pytlik R; Kalinova M; Simkovic M; Salek D; Mocikova H; Prochazka V; Blahovcova P; Janikova A; Markova J; Obr A; Berkova A; Kubinyi J; Vaskova M; Mejstrikova E; Campr V; Jaksa R; Kodet R; Michalova K; Trka J; Trneny M
Hematol Oncol; 2018 Feb; 36(1):110-115. PubMed ID: 29083050
[TBL] [Abstract][Full Text] [Related]
26. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
29. Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR).
Izutsu K; Suzumiya J; Takizawa J; Fukase K; Nakamura M; Jinushi M; Nagai H
J Clin Exp Hematop; 2021 Sep; 61(3):135-144. PubMed ID: 34092722
[TBL] [Abstract][Full Text] [Related]
30. Transplantation for mantle cell lymphoma: is it the right thing to do?
Williams ME
Hematology Am Soc Hematol Educ Program; 2013; 2013():568-74. PubMed ID: 24319233
[TBL] [Abstract][Full Text] [Related]
31. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
Thomas DW; Owen RG; Johnson SA; Hillmen P; Seymour JF; Wolf MM; Rule SA
Leuk Lymphoma; 2005 Apr; 46(4):549-52. PubMed ID: 16019483
[TBL] [Abstract][Full Text] [Related]
32. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
[TBL] [Abstract][Full Text] [Related]
33. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Shaw J; Harvey C; Richards C; Kim C
Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
36. Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy.
Alonso JJ; Cánovas A; Riñón MM
Neurologia (Engl Ed); 2018 Apr; 33(3):201-202. PubMed ID: 27126565
[No Abstract] [Full Text] [Related]
37. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
38. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
39. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Till BG
Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: a Turkish Multi-Center Study.
Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
